$SMMT (SUMMIT THERAPEUTICS) — 8-K: Updated HARMONi Data Show Ivonescimab OS Hazard Ratio of 0.76 in EGFR-Mutated NSCLC

Updated Phase III HARMONi results presented at WCLC 2026 showed ivonescimab plus chemotherapy achieved an overall survival hazard ratio of 0.76 (95% CI: 0.61-0.95; nominal p=0.0151) in the global intention-to-treat population versus placebo plus chemotherapy. The western patient subgroup demonstrated a consistent OS hazard ratio of 0.76 (95% CI: 0.52-1.10). Median follow-up for western patients was 23.2 months at the June 2026 data cut-off, versus 9.2 months at the April 2025 primary analysis, which had shown a hazard ratio of 0.79 (95% CI: 0.62-1.01; p=0.057) and median OS of 16.8 months versus 14.0 months. No new safety signals were observed.

Updated Phase III HARMONi results presented at WCLC 2026 showed ivonescimab plus chemotherapy achieved an overall survival hazard ratio of 0.76 (95% CI: 0.61-0.95; nominal p=0.0151) in the global inte